Alkahest is conducting multiple ongoing Phase II efficacy trials in diseases with critical unmet needs. Our protein-targeted interventions inhibit the negative biological chronokines that increase with age and our proprietary plasma fractions replenish the positive biological functional chronokines that decrease with age. In addition to our lead assets, other therapeutic targets designed to antagonize or supplement additional chronokine targets are in development.
|Research||IND Enabling||Phase 1||Phase 2||Phase 3|
|Alzheimer's Disease - Mild to Moderate|
|Alzheimer's Disease - Severe|
|Parkinson's Disease with Cognitive Impairment|